Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02427958
Other study ID # Leuprorelin-4001
Secondary ID U1111-1183-0353C
Status Completed
Phase Phase 4
First received
Last updated
Start date August 7, 2015
Est. completion date November 23, 2018

Study information

Verified date March 2022
Source Takeda
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess long-term safety and efficacy of leuprorelin in the treatment of Central Precocious Puberty (CPP).


Description:

The drug in this study is called leuprorelin. It is administered as a 1 month subcutaneous depot injection. Leuprorelin is used to treat children who have CPP. This study will look at whether leuprorelin can stop early puberty in pre-pubertal children. The study will enroll approximately 300 participants. Participants with body weight >=20 kg will receive the recommended dose of leuprorelin 3.75 mg subcutaneous injection every 4 weeks for 96 weeks. Participants with body weight <20 kg will receive recommended dose of 1.88 mg subcutaneous injection every 4 weeks for 96 weeks. This trial will be conducted in China. The overall time to participate in this study is 104 weeks. Participants will make 11 visits to the clinic, and will be followed-up by the physician on a long-term basis until stable puberty is reached.


Recruitment information / eligibility

Status Completed
Enrollment 307
Est. completion date November 23, 2018
Est. primary completion date November 23, 2018
Accepts healthy volunteers No
Gender All
Age group 1 Year to 9 Years
Eligibility Inclusion Criteria: 1. In the opinion of the investigator, the participant and/or parent(s) or legal guardian are capable of understanding and complying with protocol requirements. 2. The participant or the participant's parent(s) or legally acceptable representative signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures. 3. Has onset of appearance of secondary sexual characteristic earlier than age 8.0 years in girls or earlier than 9.0 years in boys and the symptom is persistent, and has confirmed diagnosis of CPP. 4. Has basal luteinizing hormone (LH) level greater than (>) 5.0 international units per liter (IU/L) or peak LH >3.3 IU/L with LH/follicle-stimulating factor (FSH) >0.6 in stimulation test. 5. Has evidence of gonadal development evaluated by ultrasonography: ovarian volume >=1 milliliter (mL) with multiple follicles >=4 millimeter (mm) in any ovary or uterine enlargement in females or testicular volume >=4 mL in males. 6. Has advanced bone age (BA) >=1 year and BA is less than or equal to (<=) 11.5 years in females or <=12.5 years in males OR predicted adult height <150 centimeter (cm) in females or <160 cm in males OR standard deviation score (SDS) <-2 standard deviations (SD) OR rapid growth defined as growth of BA /growth of chronologic age >1. BA is determined by Greulich and Pyle standards or Tanner-Whitehouse 3 (TW3) standards at screening. 7. Has anticipated treatment duration of at least 2 year in investigator's judgment. 8. A male participant who is nonsterilized and sexually active with a female partner of childbearing potential agrees to use adequate contraception from signing of informed consent throughout the duration of the study and for 90 days after last dose. 9. A female participant of childbearing potential who is sexually active with a nonsterilized male partner agrees to use routinely adequate contraception from signing of informed consent throughout the duration of the study. 10. The female participant who, at the discretion of the investigator, is deemed to be of child bearing potential must provide negative urine pregnancy text at Day -1 or Day 1 prior to drug administration. Exclusion Criteria: 1. Has received any investigational compound within 30 days prior to Screening. 2. Has received gonadotropin-releasing hormone analog (GnRHa) treatment in a previous clinical study or as a therapeutic agent. 3. Is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in the conduct of this study (example [eg], spouse, parent, child, sibling) or may consent under duress. 4. Has any findings in his/her medical history, physical examination, or safety clinical laboratory tests giving reasonable suspicion of underlying disease that might interfere with the conduct of the trial. 5. Has any concomitant medical condition that, in the opinion of the investigator, may expose a participant to an unacceptable level of safety risk or that affects participant compliance. 6. Has any screening abnormal laboratory value that suggests a clinically significant underlying disease or condition that may prevent the participant from entering the study; or the participant has: creatinine >=1.5 milligram per deciliter (mg/dL), alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) >2 times the upper limit of normal (ULN), or total bilirubin >2.0 mg/dL, with AST/ALT elevated above the limits of normal values. 7. Has a history or clinical manifestations of significant adrenal or thyroid diseases or intracranial tumor OR has a history of malignant disease. 8. Has a history of hypersensitivity or allergies to leuprorelin, or related compounds including any excipients of the compound. 9. Has a diagnosis of peripheral precocious puberty. 10. Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 1 year prior to the Screening Visit. 11. Participant or parent(s), at the discretion of the investigator, is unlikely to comply with the protocol or is unsuitable for any of other reason. 12. If female, the participant is of childbearing potential (eg, not sterilized). 13. If female, the participant is pregnant or lactating or intending to become pregnant before, during, or within 1 month after participating in this study; or intending to donate ova during such time period. 14. If male, the participant intends to donate sperm during the course of this study or for 90 days thereafter. 15. Has participated in another clinical study and/or has received any investigational compound within 30 days prior to Screening.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Leuprorelin
Suspension for injection.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Takeda

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) Day 1 up to Week 100
Secondary Percentage of Participants With Regression or no Progression in Tanner Staging at Week 96 Tanner assessment score was used to document the stage of development of puberty through the assessment of secondary sexual characteristics. Female pubertal development staged by pubic hair development and breast size; male pubertal development staged by size of the genitalia and development of pubic hair. Rated in 5 stages: stage 1 (no development) to 5 (adult-like development in quantity and size). Regression or no progression was defined as negative change (improvement) or no change in Tanner score at Week 96 compared to baseline. Week 96
See also
  Status Clinical Trial Phase
Completed NCT02920515 - Study of Comprehensive Diagnosis and Treatment for Children Precocious Puberty Phase 4
Completed NCT00779103 - Histrelin Subcutaneous Implant in Children With Central Precocious Puberty Phase 3
Not yet recruiting NCT05341128 - A Study of Medical Records From Children With Central Precocious Puberty (CPP) in China
Completed NCT04736602 - Efficacy and Safety Study of Triptorelin 3-Month Formulation in Chinese Children With Central Precocious Puberty. Phase 3
Recruiting NCT05341115 - A Study of Leuprolide Acetate Depot in Children With Central Precocious Puberty Phase 4
Completed NCT02993926 - A Study to Assess the Safety and Efficacy of Enantone (Leuprorelin) in Central Precocious Puberty (CPP) Among Chinese Participants
Recruiting NCT02811471 - Pharmacokinetic Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty Phase 3
Completed NCT03316482 - Leuprorelin Acetate DPS (Leuplin DPS) Treatment Quarterly in Patients With Central Precocious Puberty Phase 4
Recruiting NCT06129539 - A Study to Assess the Efficacy, Safety and Pharmacokinetics of Debio 4326 in Pediatric Participants Receiving Gonadotropin-Releasing Hormone Agonist Therapy for Central Precocious Puberty Phase 3
Completed NCT01634321 - The Clinical Trial to Evaluate the Efficacy and Safety of Luphere Depot Inj. 3.75mg(Leuprolide Acetate 3.75mg) in Patients With Precocious Puberty Phase 4
Terminated NCT02006680 - Markers of Pubertal Suppression During Therapy for Precocious Puberty
Completed NCT01278290 - Comparative Validation of the Triptorelin Test for the Diagnosis of CPP in Girls Phase 3
Completed NCT05029622 - A Study to Assess the Efficacy and Safety of the Triptorelin 6-month Formulation in Paediatric Participants With Central Precocious Puberty. Phase 3
Recruiting NCT06025409 - Evaluate the Efficacy and Safety of DWJ108J Phase 3
Completed NCT01467882 - Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty Phase 3
Recruiting NCT00438217 - Analysis of Genetic and Environmental Parameters Influencing Growth Rate of Precocious Puberty Children Phase 4